glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP−1 receptor agonists
Pay in 4 interest-free payments of $6.81 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP1 receptor agonists](https://www.frontiersin.org/files/Articles/1085799/xml-images/fendo-14-1085799-g001.webp)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP1 receptor agonists](https://assets.cureus.com/uploads/figure/file/1358875/article_river_6ec20b70dc8011efab01038c9fa496dc-figure1128.png)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP1 receptor agonists](https://www.apsf.org/wp-content/uploads/newsletters/2023/3803/table-1-glp-1-agonists.jpg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP1 receptor agonists](https://i.ytimg.com/vi/-MSmaL7eFHY/hq720.jpg?sqp=-oaymwE7CK4FEIIDSFryq4qpAy0IARUAAAAAGAElAADIQj0AgKJD8AEB-AH-CYAC0AWKAgwIABABGBEgaChyMA8=&rs=AOn4CLAd0vv650xm5dH5-VZ1xOhjCDzz2g)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP1 receptor agonists](https://www.thelancet.com/cms/10.1016/S0140-6736(25)02105-1/asset/8468e457-0c7f-4e4c-9b6d-2202dbefa9cb/main.assets/gr1_lrg.jpg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP1 receptor agonists](https://ajkdblog.org/wp-content/uploads/2025/09/Lee-VA.jpg)
















